Since Medikamente in der Schweiz ihr Money where?

The people took over the cost initiative in June, but the general conditions are focused on the agenda. Parliament must charge a large part of the costs. One element can put all the other masses in the balance: by using medicines, the pre-modelling can be carried out automatically. A savings account of 400 million francs per year has been created.

Compulsory credit insurance will start in 2023 with 9 million francs to cover 22 percent of healthcare costs – and production has already started in 2014. In the Gesundheitskommission des Nationalrats Stiess, the industry will die on Resonanz: The Kommission vertagte Entscheide in this Frage, bis a vertiefte Prüfung zur künftigen Preisfestsetzung vollzogen ist.

Different reviews

View the reviews of the Medicine Award in Switzerland as «overhöht». If you have a systematic cost control with the benefits, a form of winner will provide a portion of the costs. The common answer: «So something we do not have.» If you may begin, you can best label the value of the Basic Insurance bezahlten for the Zulassung of the «WZW-Test»: Effectiveness, Utility and Economics.

The Medizinische Nutsplayelt is met, but central elements for the Beurteilung van de Wirtschaftlichkeit (roads Rabatten often verzerrte) Preisvergleich with dem Ausland as well as der Preisvergleich with konkurrierende Heilmitteln. There is no question of a director Vergleich of Costs and won Lebensjahren.

The pharmaceutical industry got to work on a study by American professors Frank Lichtenberg in 2022, which has completed the financing of Novartis. Lichtenberg has revived the statistics in Switzerland from 1990 to 2011 by the Entwicklung verlorener Lebensjahre and the Spitalaufenthalte until 2018. The core collision comes in 2018: Die Kosten der Medikamente are in Mittel per gerettetes Leben sjahr gross etwa 14,000 Euro and net after the purchase of a savings account at the Spitalkosten this was more than 2000 Euro. It would be very nice. For comparison: In 2010, the Federal Court issued a Gross Ordinance of etwa 100,000 Francs per gerettetes Lebensjahr as angemessen eingeschatzt.

Unusual Estimation Method

However, Lichtenberg’s Schätz method leaves questions open. It is therefore not the case that the statistical data on new medicines and years of life gained are an indication of the best results. Factors that may have played a role in other medical improvements in the event.

Aussagekräftiger Wären systematic study of one of the new medicines – with the gegenüberstellung of the prices with the Wirkung at the bezügern. If you only do research, a medicine is only necessary. Hinweise liefern periodical Einzelstudies im Rahmen des HTA-Programmas (“Health Technology Assessment”), at the zweifelhafte Heilmittel under the Lupe kommen. So it is estimated that the 2024 Beispiel will be an HTA message, which will result in a Mittel zur Behandlung und Stoffwechselkrankheit (zystic fibrosis) with official prices in fast all Szenarien pro won Lebensjahr with fuller Gesundheit over a Million Francs cost.

Wünschbar would be a representative Zusammenstellungen of a Vielzahl umsatzstarker Heilmittel. This one couldn’t be sweeter at the Krankenkasse Helsana, it is a published Arzneimittel-Report. Gemäss der zurzeit jüngsten Aflage verursachten die 20 cost-intensive costs Präparate 2022 Gesamtkosten of 127 Millionen Francs. The range of costs for the patient was between 300 and 26,000 francs. The Helsana criticism in the message is that of 45 new medical substances of 2022 with 4 «Innovation character» aufwiesen. There are still no costs involved.

“Politics and society have not led the discussion on the value of life without health”, said the Helsana Health Surveyor Manuel Elmiger. A resolved discussion with “wünschenswert”, says Kerstin Vokinger, professor of law and meditation at the University of Zurich. There is war and there is a varied study of costs and benefits of medicines at home and abroad. The price level in Switzerland is generally higher, the lowest according to Vokinger. See further: «The prices are not optimal.» You love the individual from your studies: Fewer than a third of all refreshed supplemental medicines have a high therapeutic benefit; with credit medicines it is the case that the statistics of the medical sector are useful and affordable; and credit medication see another knife and their benefits in the middle and are as dreamlike as other Heilmittel.